Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
S. Saracchini, L. Foltran, F. Tuccia, A. Bassini +7 more
2013Breast24 citations Open access
Semantic Scholar

